Moreover, treatment of TPC-1 and BCPAP cells for 24 h with trametinib, a MEK inhibitor which was shown to reduce HMGA2 mRNA expression levels [11], increased TG, TPO and PAX8 mRNA levels (Figure 3b), suggesting that the MAPK pathway induces cell dedifferentiation in papillary thyroid carcinomas through HMGA2. Here, TPO is linked to thyroid gland papillary carcinoma.